Johnson & Johnson on May 11 appointed Thibaut Mongon as the chief executive officer of the consumer health division, which the pharmaceutical giant plans to spin off into a listed company by the end of 2023.

GlaxoSmithKline

GlaxoSmithKline exceeded expectations for the company’s first-quarter 2022 sales and earnings forecasts. This was largely driven by GSK’s sales of Xevudy, an antibody treatment against COVID-19 it developed with Vir Biotechnology, and the company’s Shingrix vaccine against shingles.

Pfizer Inc. said on April 11 that Lowe’s Cos Inc Chief Financial Officer David Denton would succeed company veteran Frank D’Amelio as the U.S. drugmaker’s finance chief.

In recognition of International Women’s Day 2022 on March 8, members of the Rare Patient Voice leadership team reflected on female leadership, team work, role models and lessons they have learned along the way.

Compas on July 27 announced a rebranding that reflects future growth of the organization and expansion of its capabilities.

Novartis CEO Joe Jimenez will step down on Feb. 1, 2018, and hand over the top leadership role of the Swiss company to drug development chief Vas Narasimhan.

July 21, 2017 By Alex Keown, BioSpace.com Breaking News Staff LONDON – After a period of uncertainty, AstraZeneca (AZN) Chief Executive Officer Pascal Soriot finally broke his silence to squelch rumors he was departing the company and urged his employees to remain focused on the company’s goals. In an internal memo sent earlier this week […]

J. Michael Pearson is out at Valeant Pharmaceuticals and the company is looking for a new chief executive officer.

BOSTON – The verdict is in and Lars Sørensenhief executive officer of the Denmark-based diabetes drugmaking giant Novo Nordisk (NVO), has been named the world’s best-performing CEO, according to the Harvard Business Review.   This year, the HBR selected Sørensen as the number one chief executive for its annual “100 Best Performing CEOs.” Sørensen, who […]